Amarin Corp ADR (AMRN)

$19.33 +0.49 (2.60%)
Market Cap 389.67M
Revenue (ttm) 228.61M
Net Income (ttm) -82.18M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 63.17
Profit Margin -35.95%
Debt to Equity Ratio 0.00
Volume 269,300
Avg Vol 72,352
Day's Range N/A - N/A
Shares Out 20.68M
Stochastic %K 79%
Beta 0.62
Analysts Buy
Price Target $11.00

Company Profile

Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally through wholesalers, selected regional wholesalers, and specialty p...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 353 0 166 99020
Address:
One Central Plaza, 5th Floor 36 Dame Street, Dublin, Ireland
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 7 at 5:38 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $AMRN Current Share Price: $20.08 Contracts: $AMRN March 20, 2026 $21 Calls Scale in: $1.88- $2.30 Scale out: $2.92-$3.76 Can Easily Capture: 60% ROI Blended DTE: 165 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
EnVila
EnVila Oct. 7 at 4:42 AM
$AMRN Recordati expects a revenue of 40 million EUR for Vazkepa in Spain in 2027: https://www.eleconomista.es/salud-bienestar/amp/13578431/recordati-inicia-la-venta-de-un-tratamiento-cardiovascular-que-facturara-40-millones-en-2027
1 · Reply
whylieineedMorleysmoney
whylieineedMorleysmoney Oct. 7 at 1:06 AM
$AMRN we need $50
0 · Reply
whylieineedMorleysmoney
whylieineedMorleysmoney Oct. 7 at 12:38 AM
$AMRN $50 is $2.50 pre split whoopie we are at a $1.00
1 · Reply
biffermeister
biffermeister Oct. 6 at 10:04 PM
$AMRN one thing going for you guys is the sloshing of money down stream from selling some of the big boys as this Trump bull market defies the odds. the oracle will not be pleased.
1 · Reply
MorrisBorris2Duex
MorrisBorris2Duex Oct. 6 at 9:15 PM
$AMRN https://finance.yahoo.com/news/amarin-amrn-surges-12-5-134100923.html
0 · Reply
Bulltrader988
Bulltrader988 Oct. 6 at 9:12 PM
$AMRN ....👃👀 https://finviz.com/quote.ashx?t=AMRN&ty=c&ta=1&p=d
1 · Reply
Starstar900
Starstar900 Oct. 6 at 9:11 PM
$AMRN -what happen to capt beer the leader - did he sell
1 · Reply
declanaidan
declanaidan Oct. 6 at 8:52 PM
$AMRN New 52-week trading high today. New 52-week closing high today. Volume today way up No news . 🤔
1 · Reply
declanaidan
declanaidan Oct. 6 at 8:10 PM
$AMRN Impressive volume here now. Volume precedes price, as the adage goes. Nice up of 2.6% in pps, albeit off the HOD and 52- high today. I'll take it and in fact prefer these slow steady back and fill climbs.
2 · Reply
Latest News on AMRN
Amarin: Vascepa's Global Pivot From U.S. Squeeze To International Boom

Sep 29, 2025, 5:52 PM EDT - 7 days ago

Amarin: Vascepa's Global Pivot From U.S. Squeeze To International Boom

Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ESC 2025

Aug 31, 2025, 8:30 AM EDT - 5 weeks ago

Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ESC 2025

New REDUCE-IT® Analyses Presented at ESC 2025 Include Data Showing VASCEPA®/VAZKEPA® (Icosapent Ethyl) Therapy Resulted in 9% Fewer Total Hospitalizations & Reduces Cardiovascular Disease Risk in Certain High-Risk Patient Subgroups

Aug 30, 2025, 8:30 AM EDT - 5 weeks ago

New REDUCE-IT® Analyses Presented at ESC 2025 Include Data Showing VASCEPA®/VAZKEPA® (Icosapent Ethyl) Therapy Resulted in 9% Fewer Total Hospitalizations & Reduces Cardiovascular Disease Risk in Certain High-Risk Patient Subgroups

New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2025

Aug 25, 2025, 8:00 AM EDT - 6 weeks ago

New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2025

Amarin Corporation plc (AMRN) Q2 2025 Earnings Call Transcript

Jul 30, 2025, 2:06 PM EDT - 2 months ago

Amarin Corporation plc (AMRN) Q2 2025 Earnings Call Transcript

Amarin Reports Second Quarter 2025 Financial Results

Jul 30, 2025, 7:00 AM EDT - 2 months ago

Amarin Reports Second Quarter 2025 Financial Results

Amarin to Report Second Quarter 2025 Financial Results and Host Conference Call on July 30, 2025

Jul 23, 2025, 7:30 AM EDT - 2 months ago

Amarin to Report Second Quarter 2025 Financial Results and Host Conference Call on July 30, 2025

RECORDATI ANNOUNCES EXCLUSIVE LICENSING & SUPPLY AGREEMENT WITH AMARIN TO COMMERCIALIZE VAZKEPA® IN EUROPE

Jun 24, 2025, 7:05 AM EDT - 3 months ago

RECORDATI ANNOUNCES EXCLUSIVE LICENSING & SUPPLY AGREEMENT WITH AMARIN TO COMMERCIALIZE VAZKEPA® IN EUROPE

Amarin Corporation plc (AMRN) Q1 2025 Earnings Call Transcript

May 7, 2025, 11:01 AM EDT - 5 months ago

Amarin Corporation plc (AMRN) Q1 2025 Earnings Call Transcript

Amarin Regains Compliance with Nasdaq Minimum Bid Price Requirement

Apr 29, 2025, 4:15 PM EDT - 5 months ago

Amarin Regains Compliance with Nasdaq Minimum Bid Price Requirement

Amarin to Report First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025

Apr 28, 2025, 4:15 PM EDT - 5 months ago

Amarin to Report First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025

Hyatt Hotels, THOR Industries And Other Big Stocks Moving Lower On Monday

Apr 14, 2025, 10:02 AM EDT - 6 months ago

Hyatt Hotels, THOR Industries And Other Big Stocks Moving Lower On Monday

H THO ALMS CCO ECX HZO NUTX

Amarin Confirms Effective Date for 1-For-20 ADS Ratio Change

Apr 9, 2025, 7:30 AM EDT - 6 months ago

Amarin Confirms Effective Date for 1-For-20 ADS Ratio Change

Amarin Appoints JEC Capital Partners' Michael Torok to Board of Directors

Apr 7, 2025, 7:30 AM EDT - 6 months ago

Amarin Appoints JEC Capital Partners' Michael Torok to Board of Directors

Concerned Shareholder Group Urges Amarin's Board of Directors to Initiate a Strategic Review Following Two Years of Underperformance

Mar 19, 2025, 12:45 PM EDT - 7 months ago

Concerned Shareholder Group Urges Amarin's Board of Directors to Initiate a Strategic Review Following Two Years of Underperformance

New Research Exploring Mechanistic Benefits of Eicosapentaenoic Acid (EPA) In Vitro on Lipoprotein(a) [Lp(a)] Oxidation and on Protein Expression in Endothelial Cells in Combination with GLP-1 Receptor Agonist to be Presented at the American College of Cardiology's (ACC) Annual Scientific Session & Expo

Mar 19, 2025, 7:30 AM EDT - 7 months ago

New Research Exploring Mechanistic Benefits of Eicosapentaenoic Acid (EPA) In Vitro on Lipoprotein(a) [Lp(a)] Oxidation and on Protein Expression in Endothelial Cells in Combination with GLP-1 Receptor Agonist to be Presented at the American College of Cardiology's (ACC) Annual Scientific Session & Expo

Amarin Corporation plc (AMRN) Q4 2024 Earnings Call Transcript

Mar 12, 2025, 10:30 AM EDT - 7 months ago

Amarin Corporation plc (AMRN) Q4 2024 Earnings Call Transcript

Amarin Marks Key Milestone for VASCEPA®/VAZKEPA® (Icosapent Ethyl) -- Publication of Post Hoc Analysis of REDUCE-IT in Journal of the American Heart Association Reports Benefit on Top of Cholesterol Lowering

Feb 27, 2025, 9:00 AM EST - 7 months ago

Amarin Marks Key Milestone for VASCEPA®/VAZKEPA® (Icosapent Ethyl) -- Publication of Post Hoc Analysis of REDUCE-IT in Journal of the American Heart Association Reports Benefit on Top of Cholesterol Lowering

Amarin to Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 12, 2025

Feb 19, 2025, 8:30 AM EST - 8 months ago

Amarin to Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 12, 2025

Amarin Receives National Reimbursement for VAZKEPA® in Italy

Dec 16, 2024, 7:00 AM EST - 10 months ago

Amarin Receives National Reimbursement for VAZKEPA® in Italy

Amarin Appoints Peter Fishman Chief Financial Officer

Dec 13, 2024, 9:00 AM EST - 10 months ago

Amarin Appoints Peter Fishman Chief Financial Officer

Top 3 Health Care Stocks You'll Regret Missing In Q4

Nov 19, 2024, 7:52 AM EST - 11 months ago

Top 3 Health Care Stocks You'll Regret Missing In Q4

SLN TERN

Amarin Corporation plc (AMRN) Q3 2024 Earnings Call Transcript

Oct 30, 2024, 8:50 PM EDT - 1 year ago

Amarin Corporation plc (AMRN) Q3 2024 Earnings Call Transcript

Research Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual European Association for the Study of Diabetes (EASD) Meeting

Sep 9, 2024, 7:30 AM EDT - 1 year ago

Research Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual European Association for the Study of Diabetes (EASD) Meeting

Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress

Aug 22, 2024, 8:30 AM EDT - 1 year ago

Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress

Amarin Corporation plc (AMRN) Q2 2024 Earnings Call Transcript

Jul 31, 2024, 12:28 PM EDT - 1 year ago

Amarin Corporation plc (AMRN) Q2 2024 Earnings Call Transcript

Amarin Reports Second Quarter 2024 Financial Results and Provides Business Update

Jul 31, 2024, 7:00 AM EDT - 1 year ago

Amarin Reports Second Quarter 2024 Financial Results and Provides Business Update

Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Portugal

Jul 17, 2024, 4:15 PM EDT - 1 year ago

Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Portugal

Amarin to Report Second Quarter 2024 Financial Results and Host Conference Call on July 31, 2024

Jul 17, 2024, 8:00 AM EDT - 1 year ago

Amarin to Report Second Quarter 2024 Financial Results and Host Conference Call on July 31, 2024

Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA® (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR)

Jul 8, 2024, 7:30 AM EDT - 1 year ago

Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA® (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR)

LA BOUTIQUE Opens Flagship Store at Gaysorn Amarin: The New Must-Visit Destination in Bangkok

Jun 7, 2024, 7:16 PM EDT - 1 year ago

LA BOUTIQUE Opens Flagship Store at Gaysorn Amarin: The New Must-Visit Destination in Bangkok

Amarin Board of Directors Announces CEO Transition

Jun 4, 2024, 7:30 AM EDT - 1 year ago

Amarin Board of Directors Announces CEO Transition

Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A.

May 28, 2024, 8:15 AM EDT - 1 year ago

Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A.

Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference

May 6, 2024, 8:00 AM EDT - 1 year ago

Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference

Amarin Corporation plc (AMRN) Q1 2024 Earnings Call Transcript

May 1, 2024, 10:43 AM EDT - 1 year ago

Amarin Corporation plc (AMRN) Q1 2024 Earnings Call Transcript

Amarin Reports First Quarter 2024 Business Update and Financial Results

May 1, 2024, 7:00 AM EDT - 1 year ago

Amarin Reports First Quarter 2024 Business Update and Financial Results

Amarin Applauds HealthyWomen's Citizen's Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event

Apr 24, 2024, 2:00 PM EDT - 1 year ago

Amarin Applauds HealthyWomen's Citizen's Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event

Amarin Announces Results of Annual General Meeting of Shareholders

Apr 22, 2024, 8:00 AM EDT - 1 year ago

Amarin Announces Results of Annual General Meeting of Shareholders

Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024

Apr 15, 2024, 8:00 AM EDT - 1 year ago

Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024

Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24

Apr 8, 2024, 8:00 AM EDT - 1 year ago

Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24

New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups

Apr 6, 2024, 3:30 PM EDT - 1 year ago

New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups

Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe

Apr 3, 2024, 8:00 AM EDT - 1 year ago

Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe

Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology's (ACC) Annual Scientific Session & Expo

Mar 25, 2024, 8:00 AM EDT - 1 year ago

Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology's (ACC) Annual Scientific Session & Expo

Amarin Corporation plc (AMRN) Q4 2023 Earnings Call Transcript

Feb 29, 2024, 10:18 AM EST - 1 year ago

Amarin Corporation plc (AMRN) Q4 2023 Earnings Call Transcript

Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Feb 29, 2024, 7:00 AM EST - 1 year ago

Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024

Feb 15, 2024, 8:00 AM EST - 1 year ago

Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024

Amarin Chairman & CEO Issue Letter to Shareholders

Jan 22, 2024, 7:30 AM EST - 1 year ago

Amarin Chairman & CEO Issue Letter to Shareholders

Amarin: Sarissa Is Giving Me Hope Again

Jan 15, 2024, 3:06 AM EST - 1 year ago

Amarin: Sarissa Is Giving Me Hope Again

Amarin Corporation plc (AMRN) CEO Pat Holt presents at 42nd Annual J.P. Morgan Healthcare Conference (Transcript)

Jan 10, 2024, 6:40 PM EST - 1 year ago

Amarin Corporation plc (AMRN) CEO Pat Holt presents at 42nd Annual J.P. Morgan Healthcare Conference (Transcript)

Amarin Provides Preliminary Fourth Quarter 2023 Selected Financials and Outlines Key Priorities For 2024

Jan 10, 2024, 7:00 AM EST - 1 year ago

Amarin Provides Preliminary Fourth Quarter 2023 Selected Financials and Outlines Key Priorities For 2024

LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 7 at 5:38 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $AMRN Current Share Price: $20.08 Contracts: $AMRN March 20, 2026 $21 Calls Scale in: $1.88- $2.30 Scale out: $2.92-$3.76 Can Easily Capture: 60% ROI Blended DTE: 165 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
EnVila
EnVila Oct. 7 at 4:42 AM
$AMRN Recordati expects a revenue of 40 million EUR for Vazkepa in Spain in 2027: https://www.eleconomista.es/salud-bienestar/amp/13578431/recordati-inicia-la-venta-de-un-tratamiento-cardiovascular-que-facturara-40-millones-en-2027
1 · Reply
whylieineedMorleysmoney
whylieineedMorleysmoney Oct. 7 at 1:06 AM
$AMRN we need $50
0 · Reply
whylieineedMorleysmoney
whylieineedMorleysmoney Oct. 7 at 12:38 AM
$AMRN $50 is $2.50 pre split whoopie we are at a $1.00
1 · Reply
biffermeister
biffermeister Oct. 6 at 10:04 PM
$AMRN one thing going for you guys is the sloshing of money down stream from selling some of the big boys as this Trump bull market defies the odds. the oracle will not be pleased.
1 · Reply
MorrisBorris2Duex
MorrisBorris2Duex Oct. 6 at 9:15 PM
$AMRN https://finance.yahoo.com/news/amarin-amrn-surges-12-5-134100923.html
0 · Reply
Bulltrader988
Bulltrader988 Oct. 6 at 9:12 PM
$AMRN ....👃👀 https://finviz.com/quote.ashx?t=AMRN&ty=c&ta=1&p=d
1 · Reply
Starstar900
Starstar900 Oct. 6 at 9:11 PM
$AMRN -what happen to capt beer the leader - did he sell
1 · Reply
declanaidan
declanaidan Oct. 6 at 8:52 PM
$AMRN New 52-week trading high today. New 52-week closing high today. Volume today way up No news . 🤔
1 · Reply
declanaidan
declanaidan Oct. 6 at 8:10 PM
$AMRN Impressive volume here now. Volume precedes price, as the adage goes. Nice up of 2.6% in pps, albeit off the HOD and 52- high today. I'll take it and in fact prefer these slow steady back and fill climbs.
2 · Reply
Novo1
Novo1 Oct. 6 at 8:09 PM
$AMRN what goes up…..must come down 😢
0 · Reply
PghKid1
PghKid1 Oct. 6 at 7:57 PM
$AMRN not a fan of this spread!!
1 · Reply
buygreensellredchop
buygreensellredchop Oct. 6 at 7:54 PM
$AMRN Knock, knock, knoching on 20's door... see you soon 😊
1 · Reply
Heavyhitter36
Heavyhitter36 Oct. 6 at 7:34 PM
$AMRN if there isn’t any news, it’s going to hurt in a few days when this sucker heads back to $15. 😆 Sometimes I think this happens for big share holders to sell some stufff to lower their exposure. We’ll see. Feel like news would have dropped
1 · Reply
Md80dog
Md80dog Oct. 6 at 7:22 PM
$AMRN
0 · Reply
Md80dog
Md80dog Oct. 6 at 7:21 PM
$AMRN $AMRN https://seekingalpha.com/article/4826739-amarin-vascepas-global-pivot-from-u-s-squeeze-to-international-boom
0 · Reply
Bulltrader988
Bulltrader988 Oct. 6 at 7:18 PM
$AMRN When $20 again? 👃👀
1 · Reply
Ilikebeinggreen
Ilikebeinggreen Oct. 6 at 6:15 PM
$AMRN Anyone day trading this is a moron. There are much better options for day trading. Treat this like a private equity asset.
0 · Reply
Ilikebeinggreen
Ilikebeinggreen Oct. 6 at 5:53 PM
$AMRN All the "chartists" analyzing this stock are being stupid.
0 · Reply
Ilikebeinggreen
Ilikebeinggreen Oct. 6 at 5:46 PM
$AMRN Day traders taking small profits. Hard to blame them. I'm loading up for the big windfall. Why settle for tens of thousands when you can go for millions.
0 · Reply
TraderRapp
TraderRapp Oct. 6 at 4:54 PM
$AMRN if your truly bullish you'll buy this dip otherwise hold you nuts and pray it doesn't drop all the way back to $16 friggin ST down this AM!
2 · Reply
yevrag
yevrag Oct. 6 at 4:53 PM
$AMRN wow not holding today so far! RSI is in overbought territory so needs a healthy pullback! To get going again
1 · Reply